| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Postoperative Complications | 34 | 2024 | 2273 | 5.700 |
Why?
|
| Hospitals | 22 | 2024 | 299 | 4.940 |
Why?
|
| Venous Thromboembolism | 13 | 2024 | 159 | 4.840 |
Why?
|
| Colorectal Neoplasms | 16 | 2024 | 980 | 4.510 |
Why?
|
| Liver Neoplasms | 15 | 2024 | 754 | 4.250 |
Why?
|
| Hepatic Artery | 9 | 2024 | 84 | 3.800 |
Why?
|
| Colonic Neoplasms | 10 | 2024 | 573 | 3.770 |
Why?
|
| Surgical Procedures, Operative | 13 | 2024 | 205 | 3.620 |
Why?
|
| Adenocarcinoma | 19 | 2023 | 1193 | 3.460 |
Why?
|
| Infusions, Intra-Arterial | 9 | 2024 | 36 | 3.280 |
Why?
|
| Patient Discharge | 13 | 2024 | 320 | 3.180 |
Why?
|
| Pancreatic Neoplasms | 16 | 2024 | 666 | 3.070 |
Why?
|
| Colectomy | 11 | 2022 | 172 | 2.960 |
Why?
|
| Neoplasms | 19 | 2023 | 3020 | 2.920 |
Why?
|
| Esophageal Neoplasms | 11 | 2024 | 331 | 2.580 |
Why?
|
| Quality Indicators, Health Care | 7 | 2021 | 146 | 2.550 |
Why?
|
| Digestive System Surgical Procedures | 7 | 2024 | 126 | 2.490 |
Why?
|
| Aftercare | 7 | 2023 | 87 | 2.470 |
Why?
|
| Appendiceal Neoplasms | 3 | 2021 | 31 | 2.180 |
Why?
|
| Quality Improvement | 18 | 2024 | 446 | 2.170 |
Why?
|
| Humans | 150 | 2024 | 88786 | 2.050 |
Why?
|
| Esophagectomy | 8 | 2021 | 92 | 1.980 |
Why?
|
| Gastrointestinal Neoplasms | 4 | 2024 | 111 | 1.960 |
Why?
|
| United States | 46 | 2024 | 6926 | 1.940 |
Why?
|
| Retrospective Studies | 45 | 2024 | 8951 | 1.900 |
Why?
|
| Patient Readmission | 11 | 2023 | 351 | 1.780 |
Why?
|
| Neoplasm Staging | 22 | 2024 | 1988 | 1.680 |
Why?
|
| Aged | 63 | 2024 | 18994 | 1.630 |
Why?
|
| Lymph Node Excision | 6 | 2023 | 220 | 1.580 |
Why?
|
| Lymph Nodes | 9 | 2023 | 548 | 1.560 |
Why?
|
| Adenocarcinoma, Mucinous | 2 | 2021 | 48 | 1.540 |
Why?
|
| Healthcare Disparities | 6 | 2024 | 404 | 1.530 |
Why?
|
| Surgical Oncology | 2 | 2022 | 27 | 1.530 |
Why?
|
| Medicare | 9 | 2023 | 422 | 1.520 |
Why?
|
| General Surgery | 6 | 2021 | 235 | 1.490 |
Why?
|
| Stomach Neoplasms | 6 | 2023 | 280 | 1.460 |
Why?
|
| Surgeons | 5 | 2021 | 247 | 1.450 |
Why?
|
| Colorectal Surgery | 3 | 2016 | 22 | 1.390 |
Why?
|
| Postoperative Care | 4 | 2016 | 228 | 1.370 |
Why?
|
| Guidelines as Topic | 2 | 2021 | 160 | 1.370 |
Why?
|
| Risk Adjustment | 9 | 2016 | 38 | 1.370 |
Why?
|
| Middle Aged | 63 | 2024 | 25759 | 1.370 |
Why?
|
| Quality of Health Care | 9 | 2022 | 384 | 1.360 |
Why?
|
| Male | 74 | 2024 | 42099 | 1.330 |
Why?
|
| Hepatectomy | 7 | 2024 | 170 | 1.320 |
Why?
|
| Female | 76 | 2024 | 45856 | 1.300 |
Why?
|
| Chemotherapy, Adjuvant | 9 | 2023 | 481 | 1.250 |
Why?
|
| Length of Stay | 8 | 2024 | 731 | 1.240 |
Why?
|
| Rectal Neoplasms | 4 | 2020 | 127 | 1.180 |
Why?
|
| Quality Assurance, Health Care | 5 | 2022 | 225 | 1.150 |
Why?
|
| Cholangiocarcinoma | 3 | 2023 | 76 | 1.050 |
Why?
|
| Neoadjuvant Therapy | 8 | 2022 | 363 | 1.040 |
Why?
|
| Chemoprevention | 3 | 2023 | 92 | 1.040 |
Why?
|
| Risk Assessment | 12 | 2020 | 2285 | 1.030 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2021 | 1354 | 1.030 |
Why?
|
| Pancreatectomy | 7 | 2019 | 158 | 1.030 |
Why?
|
| Bile Duct Neoplasms | 3 | 2023 | 90 | 1.030 |
Why?
|
| Surgical Wound Infection | 6 | 2022 | 201 | 1.030 |
Why?
|
| Registries | 7 | 2020 | 765 | 1.030 |
Why?
|
| Quality Control | 2 | 2022 | 117 | 0.980 |
Why?
|
| Treatment Outcome | 22 | 2024 | 8170 | 0.960 |
Why?
|
| Medical Oncology | 4 | 2023 | 379 | 0.950 |
Why?
|
| Infusion Pumps, Implantable | 3 | 2023 | 25 | 0.940 |
Why?
|
| Liver Failure | 2 | 2024 | 67 | 0.910 |
Why?
|
| Patient Compliance | 2 | 2016 | 230 | 0.900 |
Why?
|
| Feasibility Studies | 4 | 2023 | 777 | 0.900 |
Why?
|
| Laparoscopy | 7 | 2020 | 771 | 0.890 |
Why?
|
| Risk Factors | 20 | 2024 | 5446 | 0.890 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2021 | 831 | 0.890 |
Why?
|
| Delivery of Health Care | 2 | 2021 | 433 | 0.880 |
Why?
|
| Medicaid | 3 | 2023 | 228 | 0.850 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2022 | 17 | 0.840 |
Why?
|
| Follow-Up Studies | 19 | 2022 | 3648 | 0.830 |
Why?
|
| Health Status Disparities | 2 | 2023 | 186 | 0.830 |
Why?
|
| Practice Guidelines as Topic | 4 | 2018 | 1039 | 0.810 |
Why?
|
| Drainage | 2 | 2020 | 159 | 0.800 |
Why?
|
| Nursing Staff, Hospital | 1 | 2022 | 42 | 0.790 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2022 | 77 | 0.790 |
Why?
|
| Personnel Staffing and Scheduling | 2 | 2022 | 93 | 0.780 |
Why?
|
| Minimally Invasive Surgical Procedures | 3 | 2020 | 250 | 0.780 |
Why?
|
| Research Report | 1 | 2021 | 44 | 0.770 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2020 | 570 | 0.760 |
Why?
|
| Health Literacy | 1 | 2022 | 72 | 0.760 |
Why?
|
| Models, Statistical | 4 | 2014 | 575 | 0.750 |
Why?
|
| Prospective Payment System | 1 | 2020 | 7 | 0.720 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2024 | 2546 | 0.720 |
Why?
|
| Preoperative Care | 4 | 2019 | 395 | 0.720 |
Why?
|
| Occupational Exposure | 1 | 2021 | 83 | 0.710 |
Why?
|
| Organizational Objectives | 1 | 2020 | 24 | 0.700 |
Why?
|
| Logistic Models | 13 | 2020 | 1210 | 0.700 |
Why?
|
| Observational Studies as Topic | 1 | 2020 | 49 | 0.700 |
Why?
|
| Efficiency | 1 | 2020 | 40 | 0.690 |
Why?
|
| Comparative Effectiveness Research | 1 | 2020 | 53 | 0.690 |
Why?
|
| Continuity of Patient Care | 1 | 2021 | 172 | 0.680 |
Why?
|
| Professional Competence | 1 | 2020 | 69 | 0.680 |
Why?
|
| Product Recalls and Withdrawals | 1 | 2019 | 2 | 0.670 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2019 | 33 | 0.670 |
Why?
|
| Cholestasis | 1 | 2019 | 45 | 0.670 |
Why?
|
| Adult | 35 | 2024 | 26414 | 0.670 |
Why?
|
| Databases, Factual | 11 | 2024 | 849 | 0.660 |
Why?
|
| Statistics as Topic | 1 | 2020 | 234 | 0.660 |
Why?
|
| Anesthesia | 1 | 2021 | 169 | 0.660 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2019 | 76 | 0.650 |
Why?
|
| Hyperthermia, Induced | 1 | 2019 | 73 | 0.640 |
Why?
|
| Skin Neoplasms | 2 | 2022 | 578 | 0.630 |
Why?
|
| Hospitals, High-Volume | 3 | 2020 | 37 | 0.610 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2014 | 73 | 0.580 |
Why?
|
| Abdominal Neoplasms | 2 | 2020 | 39 | 0.570 |
Why?
|
| Endosonography | 1 | 2017 | 98 | 0.560 |
Why?
|
| Multivariate Analysis | 12 | 2019 | 986 | 0.540 |
Why?
|
| Socioeconomic Factors | 3 | 2024 | 583 | 0.530 |
Why?
|
| Elective Surgical Procedures | 3 | 2021 | 126 | 0.520 |
Why?
|
| Guideline Adherence | 5 | 2023 | 228 | 0.520 |
Why?
|
| Biomedical Research | 1 | 2020 | 397 | 0.510 |
Why?
|
| Reoperation | 5 | 2014 | 598 | 0.510 |
Why?
|
| Aged, 80 and over | 21 | 2019 | 6754 | 0.500 |
Why?
|
| Chemoradiotherapy | 3 | 2013 | 309 | 0.500 |
Why?
|
| Obesity, Morbid | 3 | 2020 | 233 | 0.490 |
Why?
|
| Precision Medicine | 1 | 2019 | 408 | 0.480 |
Why?
|
| Combined Modality Therapy | 8 | 2021 | 1708 | 0.480 |
Why?
|
| Robotic Surgical Procedures | 1 | 2019 | 300 | 0.470 |
Why?
|
| Evidence-Based Medicine | 2 | 2020 | 430 | 0.470 |
Why?
|
| Esophagoscopy | 1 | 2014 | 89 | 0.460 |
Why?
|
| Prognosis | 14 | 2023 | 3753 | 0.460 |
Why?
|
| Lymphatic Metastasis | 7 | 2023 | 502 | 0.460 |
Why?
|
| Hospital Mortality | 3 | 2013 | 387 | 0.450 |
Why?
|
| Survival Rate | 9 | 2019 | 1880 | 0.450 |
Why?
|
| Hospital Costs | 1 | 2014 | 107 | 0.450 |
Why?
|
| Hospitalization | 2 | 2023 | 873 | 0.450 |
Why?
|
| Cancer Care Facilities | 1 | 2013 | 29 | 0.440 |
Why?
|
| Research Design | 4 | 2021 | 597 | 0.440 |
Why?
|
| Biomarkers, Tumor | 2 | 2021 | 1530 | 0.430 |
Why?
|
| Efficiency, Organizational | 1 | 2013 | 59 | 0.430 |
Why?
|
| Gastrectomy | 4 | 2020 | 69 | 0.420 |
Why?
|
| Ovarian Neoplasms | 1 | 2019 | 762 | 0.420 |
Why?
|
| Tertiary Care Centers | 1 | 2013 | 102 | 0.420 |
Why?
|
| Veterans | 1 | 2013 | 83 | 0.410 |
Why?
|
| Lung Neoplasms | 3 | 2022 | 2344 | 0.410 |
Why?
|
| Antineoplastic Agents | 3 | 2019 | 2410 | 0.400 |
Why?
|
| Appendectomy | 2 | 2022 | 36 | 0.400 |
Why?
|
| Cohort Studies | 10 | 2022 | 2850 | 0.390 |
Why?
|
| Time-to-Treatment | 1 | 2013 | 111 | 0.390 |
Why?
|
| Odds Ratio | 6 | 2020 | 685 | 0.390 |
Why?
|
| Colonoscopy | 4 | 2021 | 279 | 0.390 |
Why?
|
| Thoracic Neoplasms | 1 | 2011 | 64 | 0.390 |
Why?
|
| Sigmoid Neoplasms | 1 | 2011 | 9 | 0.380 |
Why?
|
| Diverticulum, Colon | 1 | 2011 | 10 | 0.380 |
Why?
|
| Breast Neoplasms | 4 | 2019 | 2986 | 0.360 |
Why?
|
| Organizational Culture | 2 | 2020 | 32 | 0.350 |
Why?
|
| Morbidity | 2 | 2022 | 149 | 0.350 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2024 | 390 | 0.340 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2023 | 598 | 0.330 |
Why?
|
| Quality of Life | 1 | 2017 | 1658 | 0.330 |
Why?
|
| Neoplasm Invasiveness | 1 | 2011 | 575 | 0.330 |
Why?
|
| Sentinel Lymph Node | 2 | 2018 | 16 | 0.320 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2016 | 1095 | 0.320 |
Why?
|
| Pancreaticoduodenectomy | 2 | 2019 | 83 | 0.320 |
Why?
|
| Telemedicine | 2 | 2021 | 185 | 0.310 |
Why?
|
| Sentinel Lymph Node Biopsy | 4 | 2018 | 71 | 0.290 |
Why?
|
| Body Mass Index | 2 | 2011 | 765 | 0.270 |
Why?
|
| Confidence Intervals | 4 | 2014 | 226 | 0.270 |
Why?
|
| Patient Safety | 2 | 2018 | 215 | 0.270 |
Why?
|
| Focus Groups | 3 | 2021 | 166 | 0.270 |
Why?
|
| Postoperative Period | 2 | 2020 | 301 | 0.260 |
Why?
|
| Bile Ducts, Intrahepatic | 2 | 2022 | 72 | 0.260 |
Why?
|
| Outpatients | 2 | 2023 | 100 | 0.260 |
Why?
|
| Benchmarking | 3 | 2023 | 79 | 0.260 |
Why?
|
| Gastric Bypass | 2 | 2020 | 110 | 0.260 |
Why?
|
| Severity of Illness Index | 2 | 2014 | 1835 | 0.260 |
Why?
|
| Time Factors | 6 | 2020 | 5309 | 0.250 |
Why?
|
| Illinois | 3 | 2023 | 469 | 0.250 |
Why?
|
| Melanoma | 3 | 2018 | 466 | 0.250 |
Why?
|
| Fluorouracil | 2 | 2023 | 561 | 0.250 |
Why?
|
| Patient Selection | 3 | 2019 | 682 | 0.230 |
Why?
|
| Predictive Value of Tests | 4 | 2014 | 1711 | 0.230 |
Why?
|
| Drug Therapy | 2 | 2022 | 70 | 0.230 |
Why?
|
| Bariatric Surgery | 2 | 2020 | 195 | 0.230 |
Why?
|
| Prospective Studies | 6 | 2023 | 4255 | 0.230 |
Why?
|
| Analysis of Variance | 4 | 2013 | 901 | 0.230 |
Why?
|
| Decision Support Techniques | 3 | 2014 | 168 | 0.220 |
Why?
|
| Young Adult | 7 | 2019 | 6264 | 0.220 |
Why?
|
| Neoplasm Grading | 3 | 2013 | 372 | 0.210 |
Why?
|
| Thyroidectomy | 1 | 2023 | 171 | 0.210 |
Why?
|
| Reproducibility of Results | 3 | 2020 | 2750 | 0.210 |
Why?
|
| Referral and Consultation | 2 | 2018 | 341 | 0.210 |
Why?
|
| Burnout, Professional | 2 | 2021 | 100 | 0.210 |
Why?
|
| Drug Resistance, Microbial | 1 | 2022 | 75 | 0.210 |
Why?
|
| Pancreatic Fistula | 2 | 2019 | 16 | 0.210 |
Why?
|
| Esophagogastric Junction | 2 | 2012 | 34 | 0.210 |
Why?
|
| Surgery Department, Hospital | 2 | 2014 | 44 | 0.210 |
Why?
|
| Thoracotomy | 2 | 2012 | 63 | 0.200 |
Why?
|
| Emergency Service, Hospital | 2 | 2023 | 518 | 0.200 |
Why?
|
| Comprehension | 1 | 2022 | 80 | 0.200 |
Why?
|
| Pneumonectomy | 2 | 2016 | 206 | 0.200 |
Why?
|
| CA-125 Antigen | 1 | 2021 | 22 | 0.200 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2021 | 40 | 0.200 |
Why?
|
| Education, Medical, Graduate | 3 | 2021 | 390 | 0.200 |
Why?
|
| Internship and Residency | 3 | 2021 | 1041 | 0.200 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2023 | 190 | 0.200 |
Why?
|
| Communication Barriers | 1 | 2021 | 29 | 0.200 |
Why?
|
| Incidence | 2 | 2024 | 1592 | 0.190 |
Why?
|
| Office Visits | 1 | 2021 | 50 | 0.190 |
Why?
|
| Checklist | 1 | 2021 | 61 | 0.190 |
Why?
|
| Cross-Sectional Studies | 4 | 2021 | 1698 | 0.190 |
Why?
|
| Anticoagulants | 2 | 2022 | 425 | 0.190 |
Why?
|
| Propensity Score | 2 | 2019 | 146 | 0.190 |
Why?
|
| Publishing | 1 | 2021 | 90 | 0.180 |
Why?
|
| Medical Errors | 1 | 2021 | 116 | 0.180 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2020 | 22 | 0.180 |
Why?
|
| Equipment Design | 1 | 2021 | 415 | 0.170 |
Why?
|
| Margins of Excision | 1 | 2020 | 39 | 0.170 |
Why?
|
| Pelvic Neoplasms | 1 | 2020 | 45 | 0.170 |
Why?
|
| Qualitative Research | 1 | 2021 | 288 | 0.170 |
Why?
|
| Survival Analysis | 6 | 2020 | 1534 | 0.170 |
Why?
|
| Patient Preference | 1 | 2020 | 108 | 0.170 |
Why?
|
| Health Policy | 2 | 2019 | 184 | 0.170 |
Why?
|
| Patient Education as Topic | 1 | 2022 | 357 | 0.170 |
Why?
|
| Embolization, Therapeutic | 1 | 2022 | 262 | 0.170 |
Why?
|
| Gastroparesis | 1 | 2019 | 14 | 0.160 |
Why?
|
| Reference Standards | 1 | 2019 | 144 | 0.160 |
Why?
|
| Health Status Indicators | 1 | 2019 | 103 | 0.160 |
Why?
|
| Colon | 1 | 2022 | 509 | 0.160 |
Why?
|
| Physicians, Women | 1 | 2019 | 56 | 0.160 |
Why?
|
| Fundoplication | 1 | 2019 | 78 | 0.160 |
Why?
|
| SEER Program | 1 | 2019 | 197 | 0.160 |
Why?
|
| Treatment Failure | 1 | 2019 | 287 | 0.160 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2019 | 75 | 0.160 |
Why?
|
| Academic Medical Centers | 2 | 2020 | 384 | 0.160 |
Why?
|
| Health Personnel | 1 | 2020 | 210 | 0.160 |
Why?
|
| Needs Assessment | 1 | 2019 | 158 | 0.160 |
Why?
|
| Career Choice | 1 | 2019 | 148 | 0.150 |
Why?
|
| Algorithms | 2 | 2018 | 1870 | 0.150 |
Why?
|
| Communication | 1 | 2021 | 457 | 0.150 |
Why?
|
| Health Status | 1 | 2019 | 370 | 0.140 |
Why?
|
| Anti-Bacterial Agents | 1 | 2022 | 781 | 0.140 |
Why?
|
| Accreditation | 2 | 2014 | 61 | 0.140 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2018 | 112 | 0.140 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 1212 | 0.140 |
Why?
|
| Stents | 1 | 2019 | 393 | 0.140 |
Why?
|
| Learning | 1 | 2019 | 283 | 0.140 |
Why?
|
| Physical Examination | 1 | 2017 | 148 | 0.140 |
Why?
|
| Adolescent | 6 | 2019 | 9197 | 0.130 |
Why?
|
| Endoscopy | 1 | 2019 | 344 | 0.130 |
Why?
|
| Neuroendocrine Tumors | 2 | 2007 | 117 | 0.130 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 461 | 0.130 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2013 | 142 | 0.130 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 642 | 0.120 |
Why?
|
| Health Care Surveys | 2 | 2018 | 281 | 0.120 |
Why?
|
| Curriculum | 1 | 2018 | 568 | 0.120 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2021 | 2645 | 0.110 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 1113 | 0.110 |
Why?
|
| Tissue Expansion Devices | 1 | 2013 | 8 | 0.110 |
Why?
|
| Surveys and Questionnaires | 4 | 2023 | 2607 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2013 | 858 | 0.110 |
Why?
|
| Malpractice | 1 | 2013 | 57 | 0.110 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 625 | 0.110 |
Why?
|
| Cost-Benefit Analysis | 2 | 2013 | 461 | 0.110 |
Why?
|
| Breast Implants | 1 | 2013 | 25 | 0.110 |
Why?
|
| Decision Making | 1 | 2018 | 664 | 0.110 |
Why?
|
| Clinical Competence | 1 | 2018 | 782 | 0.110 |
Why?
|
| Emergency Medical Services | 1 | 2016 | 234 | 0.110 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2014 | 101 | 0.110 |
Why?
|
| Pancreatic Diseases | 1 | 2013 | 51 | 0.110 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 2012 | 0.110 |
Why?
|
| American Cancer Society | 1 | 2012 | 13 | 0.110 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2014 | 114 | 0.110 |
Why?
|
| Pandemics | 3 | 2024 | 770 | 0.100 |
Why?
|
| Prosthesis Failure | 1 | 2013 | 115 | 0.100 |
Why?
|
| Professional Practice | 1 | 2012 | 46 | 0.100 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2012 | 30 | 0.100 |
Why?
|
| Calibration | 1 | 2012 | 104 | 0.100 |
Why?
|
| Regression Analysis | 1 | 2013 | 590 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2021 | 3440 | 0.100 |
Why?
|
| Observation | 1 | 2011 | 38 | 0.100 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2011 | 23 | 0.100 |
Why?
|
| Interprofessional Relations | 1 | 2012 | 122 | 0.100 |
Why?
|
| Gastroplasty | 1 | 2011 | 25 | 0.100 |
Why?
|
| Mammaplasty | 1 | 2013 | 109 | 0.100 |
Why?
|
| Pancreas | 1 | 2013 | 244 | 0.100 |
Why?
|
| Program Evaluation | 1 | 2012 | 304 | 0.100 |
Why?
|
| Forecasting | 1 | 2012 | 305 | 0.100 |
Why?
|
| Physicians | 1 | 2018 | 689 | 0.090 |
Why?
|
| Sigmoidoscopy | 1 | 2011 | 36 | 0.090 |
Why?
|
| False Negative Reactions | 1 | 2011 | 63 | 0.090 |
Why?
|
| Geriatric Assessment | 1 | 2012 | 182 | 0.090 |
Why?
|
| Age Factors | 4 | 2020 | 1861 | 0.090 |
Why?
|
| Abdominal Pain | 1 | 2011 | 138 | 0.090 |
Why?
|
| Piperazines | 1 | 2011 | 283 | 0.080 |
Why?
|
| Job Satisfaction | 2 | 2019 | 76 | 0.080 |
Why?
|
| Bone Neoplasms | 1 | 2011 | 328 | 0.080 |
Why?
|
| Pyrimidines | 1 | 2011 | 372 | 0.080 |
Why?
|
| Hospitals, Veterans | 1 | 2007 | 21 | 0.080 |
Why?
|
| Hospitals, Community | 2 | 2023 | 32 | 0.080 |
Why?
|
| Principal Component Analysis | 2 | 2019 | 160 | 0.070 |
Why?
|
| Florida | 1 | 2023 | 56 | 0.060 |
Why?
|
| California | 1 | 2023 | 143 | 0.060 |
Why?
|
| Yttrium Radioisotopes | 1 | 2022 | 58 | 0.050 |
Why?
|
| Rural Population | 1 | 2022 | 142 | 0.050 |
Why?
|
| Obesity | 1 | 2008 | 960 | 0.050 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2013 | 295 | 0.050 |
Why?
|
| Patient Outcome Assessment | 1 | 2021 | 84 | 0.050 |
Why?
|
| Hospitals, Low-Volume | 1 | 2020 | 18 | 0.040 |
Why?
|
| Self Report | 1 | 2021 | 295 | 0.040 |
Why?
|
| Sexual Harassment | 1 | 2019 | 9 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 2019 | 270 | 0.040 |
Why?
|
| Intraabdominal Infections | 1 | 2019 | 10 | 0.040 |
Why?
|
| Gastric Emptying | 1 | 2019 | 25 | 0.040 |
Why?
|
| Ablation Techniques | 1 | 2019 | 36 | 0.040 |
Why?
|
| Hysterectomy | 1 | 2020 | 150 | 0.040 |
Why?
|
| Hospital Bed Capacity | 1 | 2018 | 20 | 0.040 |
Why?
|
| Health Surveys | 1 | 2019 | 240 | 0.040 |
Why?
|
| ROC Curve | 2 | 2013 | 775 | 0.040 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2019 | 35 | 0.040 |
Why?
|
| Insurance Claim Review | 1 | 2018 | 45 | 0.040 |
Why?
|
| Reimbursement, Incentive | 1 | 2018 | 37 | 0.040 |
Why?
|
| Ownership | 1 | 2018 | 26 | 0.040 |
Why?
|
| Axilla | 1 | 2018 | 104 | 0.040 |
Why?
|
| Operative Time | 1 | 2018 | 138 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2019 | 1057 | 0.040 |
Why?
|
| Smoking | 1 | 2021 | 620 | 0.040 |
Why?
|
| Data Interpretation, Statistical | 1 | 2018 | 299 | 0.040 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2020 | 294 | 0.030 |
Why?
|
| Consensus | 1 | 2018 | 353 | 0.030 |
Why?
|
| Carcinoma | 1 | 2020 | 442 | 0.030 |
Why?
|
| Prostatectomy | 1 | 2020 | 476 | 0.030 |
Why?
|
| Observer Variation | 1 | 2018 | 609 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 277 | 0.030 |
Why?
|
| Renal Insufficiency | 1 | 2016 | 98 | 0.030 |
Why?
|
| Relative Value Scales | 1 | 2014 | 9 | 0.030 |
Why?
|
| Lawyers | 1 | 2013 | 2 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2014 | 94 | 0.030 |
Why?
|
| Ulcer | 1 | 2013 | 37 | 0.030 |
Why?
|
| Breast Implantation | 1 | 2013 | 13 | 0.030 |
Why?
|
| Mitosis | 1 | 2013 | 152 | 0.030 |
Why?
|
| Medicine | 1 | 2013 | 91 | 0.030 |
Why?
|
| Medical Records | 1 | 2013 | 120 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 360 | 0.030 |
Why?
|
| Insurance, Health | 1 | 2013 | 159 | 0.030 |
Why?
|
| Imatinib Mesylate | 1 | 2011 | 127 | 0.020 |
Why?
|
| Child | 1 | 2022 | 7112 | 0.020 |
Why?
|
| Mastectomy | 1 | 2013 | 245 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 848 | 0.020 |
Why?
|
| Benzamides | 1 | 2011 | 237 | 0.020 |
Why?
|
| Sepsis | 1 | 2014 | 320 | 0.020 |
Why?
|
| Weight Loss | 1 | 2011 | 225 | 0.020 |
Why?
|
| Comorbidity | 1 | 2013 | 948 | 0.020 |
Why?
|
| Disease Management | 1 | 2011 | 328 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2013 | 1107 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 2020 | 1766 | 0.020 |
Why?
|
| Laparotomy | 1 | 2008 | 67 | 0.020 |
Why?
|
| Adenoma, Islet Cell | 1 | 2007 | 28 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 306 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2011 | 565 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2007 | 94 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2007 | 1521 | 0.010 |
Why?
|